Loading...
Market
FDA approval for RYBREVANT and LAZCLUZE as first-line lung cancer treatment by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official FDA announcements and press releases
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
Roche • 25%
Pfizer • 25%
Other • 25%
AstraZeneca/Daiichi Sankyo • 25%
EMA only • 25%
FDA only • 25%
Neither • 25%
Both FDA and EMA • 25%
Yes • 50%
No • 50%
Conditional Approval • 25%
Accelerated Approval • 25%
Full Approval • 25%
No Approval • 25%
